Lymphoma
Conditions
Keywords
recurrent adult Burkitt lymphoma, recurrent adult diffuse large cell lymphoma, recurrent adult diffuse mixed cell lymphoma, recurrent adult diffuse small cleaved cell lymphoma, recurrent adult grade III lymphomatoid granulomatosis, recurrent adult immunoblastic large cell lymphoma, recurrent adult lymphoblastic lymphoma, recurrent grade 3 follicular lymphoma, recurrent mantle cell lymphoma, adult grade III lymphomatoid granulomatosis
Brief summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving bortezomib together with gemcitabine hydrochloride and rituximab may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of bortezomib and gemcitabine hydrochloride when given together with rituximab and to see how well they work in treating patients with progressive or relapsed B-cell non-Hodgkin lymphoma.
Detailed description
OBJECTIVES: Primary: I. To evaluate the safety and feasibility of combining VELCADE (bortezomib) with gemcitabine (gemcitabine hydrochloride) in patients with recurrent lymphoma after standard therapy. II. To define the maximum tolerated dose (MTD) of gemcitabine and Rituxan (rituximab) administered in combination with VELCADE given on a 21-day (old schema - Schema I) or 28-day (amended schema - Schema II) schedule. Secondary: I. To obtain preliminary data for response to this regimen in this patient population. OUTLINE: This is a phase I, dose-escalation study of bortezomib and gemcitabine hydrochloride followed by a phase II study. Patients receive bortezomib intravenously (IV), gemcitabine hydrochloride IV over 3-4 hours, and rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up periodically.
Interventions
BIOLOGICALrituximab
Given IV
DRUGbortezomib
Given IV
DRUGgemcitabine hydrochloride
Given IV
OTHERquestionnaire administration
Ancillary studies
Sponsors
National Cancer Institute (NCI)
City of Hope Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed intermediate or high grade B-cell Non-Hodgkin lymphoma with primary progressive or relapsed disease * Patients may have had up to 4 prior chemo-and-or radiation therapy regiments, including one autologous transplant based protocol; any prior therapy (chemotherapy or radiation) must have been completed at least 4 weeks prior to start of this protocol; for prior high-dose chemotherapy with stem cell transplant, a 6-week interval is required; all side effects must have resolved * Karnofsky performance status \>= 60% * Life expectancy of greater than 3 months * Absolute neutrophil count \>= 1,500 mm\^3 * Platelets \>= 50,000 mm\^3 * Total bilirubin =\< 1.5 mg/dl * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) =\< 2.5 x institutional upper limit of normal * Creatinine within normal institutional limits OR creatinine clearance \>= 50 mL/min for creatinine levels above institutional normal (calculated or measured) * Cardiac ejection fraction of \> 40% by echocardiogram or multi gated acquisition (MUGA) scan * Have no serious or intercurrent medical illness * Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study * Male subject agrees to use an acceptable method for contraception for the duration of the study
Exclusion criteria
* Patient has a platelet count of \< 20 x 10\^9/L with 7 days before enrollment * Patient has an absolute neutrophil count of \< 1.0 x 10\^9/L within 7 days before enrollment * Patient has a calculated or measured creatinine clearance of \< 30 ml/min with 14 days before enrollment * Patient has \>= Grade 2 peripheral neuropathy within 14 days before enrollment * Patient has hypersensitivity to bortezomib, boron, or mannitol * Female subject is pregnant or breastfeeding; confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening; pregnancy testing is not required for postmenopausal or surgically sterilized women * Patient has received other investigational drugs with 14 days before enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study * Patients who have had more than 4 prior different chemotherapy regimens will be excluded; patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for autologous transplant regimens) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier * Patients may not have previously received VELCADE or gemcitabine * Patients with active central nervous system (CNS) involvement are not eligible * Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 28 days from start of treatment, up to 2 years. | Adverse events were graded by NCI CTCAE, Version 3.0. DLT defined as grade 4 thrombocytopenia, or grade 3 thrombocytopenia lasting greater than 7 days. Grade 4 neutropenia lasting 7 days or more despite use of growth factors. Febrile neutropenia only is it occurs after 7 days of neutropenia. Any grade 3 or higher non-hematologic toxicity related to the study drug, with the exception of alopecia, inadequately treated nausea, vomiting and/or diarrhea and fatigue. |
| Recommended Phase II Dose | 28 days from start of treatment, up to 2 years. | The maximum tolerated dose (MTD) of Gemcitabine in combination with 1.3 mg/m2 of velcade on days 1 and 15 is based on toxicities observed during the first cycle and is defined as the highest dose tested in which fewer than 33% of patients experience an attributable DLT to the study drug, when at least 6 patients are treated at that dose and are evaluable for toxicity. Dose escalations proceeded according to a standard 3+3 design. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Subject With Complete Response | Up to 1 year | Per standard lymphoma response criteria (Cheson): Complete Response (CR), 1. Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related symptoms if present before therapy, with normalization of LDH if elevated prior to therapy. 2. All lymph nodes and masses must regress to normal size (\<1.5 cm in greatest transverse diameter if \>1.5 cm prior to treatment). 3. The spleen, if enlarged prior to therapy, must have regressed to normal size. 3. If bone marrow was involved by lymphoma, it must be cleared as documented by biopsy at the same location. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Dose Level 1 Tx Schema I - Velcade 1.0 mg/m2, Gemcitabine 1000 mg/m2 Patients receive 1.0 mg/m2 of velcade IV days 1, 4, 8, 11, and 1000 mg/m2 of gemcitabine hydrochloride IV over 3-4 hours. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 4 |
| Dose Level Tx Schema I -1 - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 Patients receive 1.0 mg/m2 of velcade IV days 1, 4, 8, 11, and 800 mg/m2 of gemcitabine hydrochloride IV over 3-4 hours. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 5 |
| Dose Level 3B Tx Schema II - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 Patients receive 1.0 mg/m2 of velcade IV days 1, 15, and 800 mg/m2 of gemcitabine hydrochloride IV over 3-4 hours. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 4 |
| Dose Level 4B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 800 mg/m2 Patients receive 1.3 mg/m2 of velcade IV days 1, 15, and 800 mg/m2 of gemcitabine hydrochloride IV over 3-4 hours. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 3 |
| Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2 Patients receive 1.3 mg/m2 of velcade IV days 1, 15, and 1000 mg/m2 of gemcitabine hydrochloride IV over 3-4 hours. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 6 |
| Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2, Rituximab 375 mg/m2 Patients receive 1.3 mg/m2 of velcade IV days 1, 15, and 800 mg/m2 of gemcitabine hydrochloride IV over 3-4 hours 375 mg/m2 of rituximab IV on days 1 and 15. Treatment repeats every 28 days for at least 6 courses in the absence of disease progression or unacceptable toxicity. | 11 |
| Total | 33 |
Baseline characteristics
| Characteristic | Total | Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2, Rituximab 375 mg/m2 | Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2 | Dose Level 4B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 800 mg/m2 | Dose Level 3B Tx Schema II - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 | Dose Level Tx Schema I -1 - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 | Dose Level 1 Tx Schema I - Velcade 1.0 mg/m2, Gemcitabine 1000 mg/m2 |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 65 years | 66 years | 72 years | 66 years | 58 years | 50 years | 60 years |
| Race/Ethnicity, Customized African American | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 5 Participants | 0 Participants | 3 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants |
| Race/Ethnicity, Customized Hispanic | 4 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown | 1 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized White Non-Hispanic | 22 Participants | 8 Participants | 3 Participants | 2 Participants | 2 Participants | 4 Participants | 3 Participants |
| Region of Enrollment United States | 33 participants | 11 participants | 6 participants | 3 participants | 4 participants | 5 participants | 4 participants |
| Sex: Female, Male Female | 10 Participants | 4 Participants | 2 Participants | 0 Participants | 0 Participants | 1 Participants | 3 Participants |
| Sex: Female, Male Male | 23 Participants | 7 Participants | 4 Participants | 3 Participants | 4 Participants | 4 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 3 / 4 | 4 / 5 | 4 / 4 | 3 / 3 | 4 / 6 | 10 / 11 |
| other Total, other adverse events | 4 / 4 | 5 / 5 | 4 / 4 | 3 / 3 | 6 / 6 | 11 / 11 |
| serious Total, serious adverse events | 3 / 4 | 3 / 5 | 3 / 4 | 0 / 3 | 0 / 6 | 4 / 11 |
Outcome results
Primary
Number of Participants With at Least One Dose Limiting Toxicity (DLT)
Adverse events were graded by NCI CTCAE, Version 3.0. DLT defined as grade 4 thrombocytopenia, or grade 3 thrombocytopenia lasting greater than 7 days. Grade 4 neutropenia lasting 7 days or more despite use of growth factors. Febrile neutropenia only is it occurs after 7 days of neutropenia. Any grade 3 or higher non-hematologic toxicity related to the study drug, with the exception of alopecia, inadequately treated nausea, vomiting and/or diarrhea and fatigue.
Time frame: 28 days from start of treatment, up to 2 years.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1 Tx Schema I - Velcade 1.0 mg/m2, Gemcitabine 1000 mg/m2 | Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 3 Participants |
| Dose Level Tx Schema I -1 - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 | Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 1 Participants |
| Dose Level 3B Tx Schema II - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 | Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 0 Participants |
| Dose Level 4B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 800 mg/m2 | Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 0 Participants |
| Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2 | Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 0 Participants |
| Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2, Rituximab 375 mg/m2 | Number of Participants With at Least One Dose Limiting Toxicity (DLT) | 0 Participants |
Primary
Recommended Phase II Dose
The maximum tolerated dose (MTD) of Gemcitabine in combination with 1.3 mg/m2 of velcade on days 1 and 15 is based on toxicities observed during the first cycle and is defined as the highest dose tested in which fewer than 33% of patients experience an attributable DLT to the study drug, when at least 6 patients are treated at that dose and are evaluable for toxicity. Dose escalations proceeded according to a standard 3+3 design.
Time frame: 28 days from start of treatment, up to 2 years.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Dose Level 1 Tx Schema I - Velcade 1.0 mg/m2, Gemcitabine 1000 mg/m2 | Recommended Phase II Dose | 1000 mg/m^2 |
Secondary
Number of Subject With Complete Response
Per standard lymphoma response criteria (Cheson): Complete Response (CR), 1. Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease related symptoms if present before therapy, with normalization of LDH if elevated prior to therapy. 2. All lymph nodes and masses must regress to normal size (\<1.5 cm in greatest transverse diameter if \>1.5 cm prior to treatment). 3. The spleen, if enlarged prior to therapy, must have regressed to normal size. 3. If bone marrow was involved by lymphoma, it must be cleared as documented by biopsy at the same location.
Time frame: Up to 1 year
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Dose Level 1 Tx Schema I - Velcade 1.0 mg/m2, Gemcitabine 1000 mg/m2 | Number of Subject With Complete Response | 1 Participants |
| Dose Level Tx Schema I -1 - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 | Number of Subject With Complete Response | 0 Participants |
| Dose Level 3B Tx Schema II - Velcade 1.0 mg/m2, Gemcitabine 800 mg/m2 | Number of Subject With Complete Response | 0 Participants |
| Dose Level 4B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 800 mg/m2 | Number of Subject With Complete Response | 0 Participants |
| Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2 | Number of Subject With Complete Response | 1 Participants |
| Dose Level 5B Tx Schema II - Velcade 1.3 mg/m2, Gemcitabine 1000 mg/m2, Rituximab 375 mg/m2 | Number of Subject With Complete Response | 1 Participants |